

**AstraZeneca – Call For Grant Applications**  
**CGA Respiratory\_Severe Asthma\_Airway Epithelium**

<b>Submission Deadline</b>	Rolling review, with submission deadline of March 25, 2022 at 12 noon EST
<b>Primary Area of Focus</b>	Respiratory
<b>Therapeutic Area</b>	Severe asthma
<b>Need</b>	<p>Airway diseases are heterogeneous in nature, with inflammation resulting from complex, variable, and dynamic interactions between airway structural cells and the innate/adaptive immune system.</p> <p>Epithelial cytokines or alarmins (including TSLP, IL-33 and IL-25) have been found to be upstream mediators/drivers in the pathophysiology of severe asthma. Results of clinical trials have shown the benefits of targeting epithelial alarmins on the management of severe asthma.</p>
<b>Educational Program</b>	Accredited scientific/medical education that is being designed and implemented for US asthma specialists (allergist/immunologists and pulmonologists) and affiliated advance practice providers to improve their knowledge of the airway epithelium and implications for the management of patients with severe asthma.
<b>Budget</b>	≤ \$175,000.00
<b>Successful submission</b>	<ul style="list-style-type: none"> <li>• Independently-developed application, providing rationale for and detailed description of the goals, learning objectives, educational strategy, format, execution and measurement of program</li> <li>• Proposed activity(ies) will: <ul style="list-style-type: none"> <li>○ Leverage the latest digital technologies for learner engagement and comprehension of the content</li> <li>○ Employ educational strategies for maximal retention and application of content by tailoring to the specific needs of and learning styles of the proposed audience</li> </ul> </li> <li>• Meaningful outcomes from previously executed programs with similar goal and format</li> <li>• Ability to achieve Level 4 outcomes, report monthly metrics / quarterly outcomes (broken down by specialty, profession and geography)</li> <li>• Both more traditional and novel/innovative program designs are welcome</li> </ul>
<b>CGA Code</b>	CGA Respiratory_Severe Asthma_Airway Epithelium
<b>Website URL</b>	<a href="https://www.astrazenecagrants.com/us-grants.html">https://www.astrazenecagrants.com/us-grants.html</a>

**Program Requirements:**

The Program must be planned and executed as an accredited activity and fully compliant with the criteria and/or standards of commercial support for ACCME, AAFP, AOA, ACPE, ANCC, AANP, or NCCPA. Furthermore, the program will be educational and non-promotional in nature and will be planned, designed and implemented in accordance with the U.S. Food and Drug Administration's Guidance on Industry-Supported Scientific and Educational Activities ("Policy Statement").

The Policy Statement and the ACCME Standards require, among other things, that (i) Institution conduct the Program independently and without control or influence by AstraZeneca over the Program's planning, content (including the selection of speakers or moderators), or execution; (ii) the Program be free of commercial bias for or against any product; (iii) Institution make meaningful disclosure of AstraZeneca support of the Program and any prior relationship between Institution and AstraZeneca, and the relationship, if any, between AstraZeneca and the speakers selected by Institution; and (iv) AstraZeneca not engage in, and Institution not permit any other sponsor to engage in, promotional activities in or near the Program room or advertise its products in any materials disseminated as part of the Program.

In addition, Institution is required by the Policy Statement and, if applicable, accreditation standards to ensure that any product discussions at the Program be accurate, objective, balanced and scientifically rigorous. This includes a balanced discussion of each product and of treatment alternatives, that limitations on data be disclosed, that unapproved uses be identified as such, and that for live presentations there be opportunities for questioning or debate.